These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 30945330)

  • 21. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
    Moreton P; Kennedy B; Lucas G; Leach M; Rassam SM; Haynes A; Tighe J; Oscier D; Fegan C; Rawstron A; Hillmen P
    J Clin Oncol; 2005 May; 23(13):2971-9. PubMed ID: 15738539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?
    Bertuglia G; Cani L; Larocca A; Gay F; D'Agostino M
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements.
    Cedena MT; Martin-Clavero E; Wong S; Shah N; Bahri N; Alonso R; Barcenas C; Valeri A; Salazar Tabares J; Sanchez-Pina J; Cuellar C; Martin T; Wolf J; Lahuerta JJ; Martinez-Lopez J
    PLoS One; 2020; 15(8):e0237155. PubMed ID: 32866200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma.
    Putkonen M; Kairisto V; Juvonen V; Pelliniemi TT; Rauhala A; Itälä-Remes M; Remes K
    Eur J Haematol; 2010 Nov; 85(5):416-23. PubMed ID: 20722702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is molecular remission the goal of multiple myeloma therapy?
    Davies FE
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):205-211. PubMed ID: 29222257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.
    Munshi NC; Avet-Loiseau H; Rawstron AC; Owen RG; Child JA; Thakurta A; Sherrington P; Samur MK; Georgieva A; Anderson KC; Gregory WM
    JAMA Oncol; 2017 Jan; 3(1):28-35. PubMed ID: 27632282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.
    Liu D; Lin P; Hu Y; Zhou Y; Tang G; Powers L; Medeiros LJ; Jorgensen JL; Wang SA
    J Clin Pathol; 2012 Sep; 65(9):823-9. PubMed ID: 22685235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.
    Martinez-Lopez J; Lahuerta JJ; Pepin F; González M; Barrio S; Ayala R; Puig N; Montalban MA; Paiva B; Weng L; Jiménez C; Sopena M; Moorhead M; Cedena T; Rapado I; Mateos MV; Rosiñol L; Oriol A; Blanchard MJ; Martínez R; Bladé J; San Miguel J; Faham M; García-Sanz R
    Blood; 2014 May; 123(20):3073-9. PubMed ID: 24646471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
    Martinez-Lopez J; Alonso R; Wong SW; Rios R; Shah N; Ruiz-Heredia Y; Sanchez-Pina JM; Sanchez R; Bahri N; Zamanillo I; Poza M; Buenache N; Encinas C; Juarez L; Miras F; Collado L; Barrio S; Martin T; Cedena MT; Wolf J
    J Hematol Oncol; 2021 Aug; 14(1):126. PubMed ID: 34404440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MRD Assessment in Multiple Myeloma: Progress and Challenges.
    Bertamini L; D'Agostino M; Gay F
    Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
    Kothari S; Hillengass J; McCarthy PL; Holstein SA
    Curr Hematol Malig Rep; 2019 Feb; 14(1):39-46. PubMed ID: 30671912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
    Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
    Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
    Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
    JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.
    Landgren O; Owen RG
    Cytometry B Clin Cytom; 2016 Jan; 90(1):14-20. PubMed ID: 26147584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantification of bone-marrow plasma cell levels using various International Myeloma Working Group response criteria in patients with multiple myeloma.
    Narita K; Kobayashi H; Abe Y; Kitadate H; Takeuchi M; Matsue K
    Int J Hematol; 2018 Oct; 108(4):371-374. PubMed ID: 29978432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.
    Bertamini L; Oliva S; Rota-Scalabrini D; Paris L; Morè S; Corradini P; Ledda A; Gentile M; De Sabbata G; Pietrantuono G; Pascarella A; Tosi P; Curci P; Gilestro M; Capra A; Galieni P; Pisani F; Annibali O; Monaco F; Liberati AM; Palmieri S; Luppi M; Zambello R; Fazio F; Belotti A; Tacchetti P; Musto P; Boccadoro M; Gay F
    J Clin Oncol; 2022 Sep; 40(27):3120-3131. PubMed ID: 35666982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.
    Alaterre E; Raimbault S; Garcia JM; Rème T; Requirand G; Klein B; Moreaux J
    Cytometry B Clin Cytom; 2018 May; 94(3):484-492. PubMed ID: 28865180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Short NJ; Kantarjian HM; Sasaki K; Cortes JE; Ravandi F; Thomas DA; Garcia-Manero G; Khouri I; Kebriaei P; Champlin RE; Pierce S; Issa GC; Konopleva M; Kadia TM; Bueso-Ramos C; Khoury JD; Jain N; O'Brien SM; Jabbour E
    Cancer; 2016 Dec; 122(24):3812-3820. PubMed ID: 27508525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adaptation of a multiple myeloma minimal residual disease multicolor flow cytometry assay for real-world practice.
    McMillan A; Tran TA; Galas-Filipowicz D; Camilleri M; Lecat C; Ainley L; Guo Y; Yong K; Sive J
    Cytometry B Clin Cytom; 2023 Jul; 104(4):304-310. PubMed ID: 36370149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.